Immune checkpoint inhibitor-related acral vasculitis

Area of Science:

• Immunology
• Oncology
• Dermatology

Background:

• Immune checkpoint inhibitors (ICIs) like anti-CTLA-4 and anti-PD-L1 are used in cancer therapy.
• Vasculitis is a known, albeit rare, side effect of ICI treatment.
• Previous reports documented ipilimumab-induced vasculitis in melanoma patients.

Purpose of the Study:

• To report a case of acral vasculitis associated with a combination of anti-CTLA-4 (tremelimumab) and anti-PD-L1 (durvalumab).
• To compare the clinical presentation and treatment response with previously reported cases of ICI-induced vasculitis.

Main Methods:

• Case report of a patient with metastatic urothelial bladder cancer.
• Treatment involved a combination regimen of tremelimumab and durvalumab.
• Clinical observation and assessment of treatment response to corticosteroids.

Main Results:

• The patient developed acral vasculitis during combination ICI therapy.
• Unlike previous reports, this case showed significant improvement with oral corticosteroids.
• This suggests a potentially different management approach for this specific ICI-induced vasculitis.

Conclusions:

• Combination anti-CTLA-4 and anti-PD-L1 therapy can induce acral vasculitis.
• Oral corticosteroids may be an effective treatment for this adverse event.
• Further research is needed to understand ICI-induced vasculitis mechanisms and optimal management strategies.